Bridge from

Science to Business

Diagenics SE ist ein biopharmazeutisches Unternehmen mit Sitz in Luxemburg.

Unser einzigartiges Modell schlägt die Brücke zwischen Wirtschaft und Wissenschaft.

Produkte

DIACORDON - POCT

POINT-OF-CARE TEST

The Point Of Care Test (POCT) is the successor of the ELISA Test and an important supplement for the emergency ambulances. It is a quick and qualitative test for making the first decisions. Point Of Care Tests are always advantageous, since they can provide a diagnosis without the laboratory support.

DIACORDON™ POCT is a stripe test (lateral flow), which also functions on the GPBB basis. Its various layers are plated with small traces of monoclonal catch-antibody of GPBB. Another antibody, responsible for the colouring, is applied on the other side. Once the blood sample runs on the absorbent strap on the antibody track, GPBB is caught by the antibodies and made visible with the help of the antibody colouring. 50 µl are enough to gain a solid result. The time for testing only takes about 15 minutes.

Until now there is no early and reliable heart specific test. Therefore, it is very difficult for doctors to rule out an infarction incidence without invasive diagnostics. Diagenics offers its patented GPBB blood test for an indication group, which knows no other alternatives. Thus, DIACORDON™ is progressive in the field of heart diseases diagnostics.

Another interesting patient group endorses those who had an open heart operation and who often suffer from a destruction of the heart muscle cells under use of a heart-lung machine. DIACORDON™ can help monitoring these patients within the first 12 to 18 hours (as long as GPBB is traceable) after the operation.

The well defined goal of Diagenics is to establish DIACORDON™ as a “gold standard” for the diagnosis and monitoring of myocardial ischemia. Once the first results can be confirmed, the test can be initiated for use as a rapid test in ambulances, in emergency rooms, in doctor offices or next to the patient bed.

The test is simple, fast, safe, dependable and sensitive. At the moment there are discussions with leading active pharmaceutical companies concerning its marketing worldwide.

DIACORDON - ELISA

LABORATORY TEST

DIACORDON™ is a blood test for the early detection of cardiac infarction. It works on an enzyme basis and can detect Glycogen-Phosphorylase Isoenzym BB (GPBB) via an antibody owned by Diagenics.

The enzyme GPBB enters the bloodstream as soon as a myocardial ischemia occurs. In the long run such an insufficient oxygen supply leads to a necrosis of the affected cells and/or eventually to an infarction. Moreover, the detection of GPBB in the blood provides information about the progress of the coronary syndromes (including unstable angina pectoris) and classic cases of heart attack. In this way it contributes decisively to the diagnosis of heart infarction patients.

There are already markers, such as myoglobin and troponin, which contribute to the diagnosis and are routinely applied in cases of a myocardial infarction. Myoglobin, however, has the disadvantage of not being heart specific. It can also be detected after damages of the skeletal muscles or after acute renal failure and thus does not give a clear answer. Troponin, on the other hand, is heart specific, but can only be detected three to six hours after the first symptoms (chest pain).

GPBB is not only heart specific but also early detectable, i.e. within the first hour. For the case of acute coronary syndromes this is a vital advantage, since a quick and exact diagnosis can save lives.

In-Licensing

Our criterias for In-licensing

Diagenics acquires promising patents and/or licenses, enters into collaborations or joint ventures, or issues licenses to high-performing partners. It is our objective to place know-how and capital selectively in order to achieve a meaningful return on investment. Based on analysis and recommendations of our scientists, our internationally experienced executives will enter negotiations with our prospective or established partners worldwide. It is likely that innovative models will emerge for many of our projects that promote progress in biotechnology and create lasting values for all parties involved.

Our In-licensing strategy in an interactive Flash-Movie

Our targets are innovative projects (companies, licenses, patents, scientific projects etc.) in the biopharmaceutical sector which can be developed to late stage development. We require a clear proof of principle and, a first approach to design a real product with a high market potential. Our focus depends upon products which can be produced and sold profitably. We will co-develop your early project to a later stage. We may be able to increase the value of the investment, with further improvement of the product. This will hopefully enhance the quality of our intellectual property rights, and subsequent FDA, EMEA, and MH&W approvals.

What do we provide for our selected partners?

The final product will be developed faster and thereby enter the market sooner. We shall provide sufficient funds necessary for improving product design and finalize programs required to demonstrate clinical relevance. These efforts will transform the initial project into a final product ready to be marketed.

You will get support on all levels, including an international infrastructure which provides both intellectual and capital resources.

We will discuss the best ways to customize the alliance to meet all specific needs. We shall tailor the project to achieve both your goals and our goals. Only if we can mutually profit, motivation and investment are guaranted. It will in any case be a challenge to mature and finally develop the project to the desired stage. We hope to increase the strategic value of the resulting product substantially. If you are interested in a cooperation please contact us here.